UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Journal of cystic fibrosis, 2020-09, Vol.19 (5), p.677-687

2020

Volltextzugriff (PDF)

Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis

American journal of respiratory and critical care medicine, 2003-03, Vol.167 (6), p.841-849

2003

Volltextzugriff (PDF)

Inflammatory and Microbiologic Markers in Induced Sputum after Intravenous Antibiotics in Cystic Fibrosis

American journal of respiratory and critical care medicine, 2003-12, Vol.168 (12), p.1471-1475

2003

Volltextzugriff (PDF)

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

American journal of respiratory and critical care medicine, 2008-11, Vol.178 (9), p.921-928

2008

Volltextzugriff (PDF)

WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species ( BURK ) infection: final results from a randomized, placebo-controlled trial

Journal of cystic fibrosis, 2012-06, Vol.11, p.S11-S11

2012

Volltextzugriff (PDF)

58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection

Journal of cystic fibrosis, 2012-06, Vol.11, p.S71-S71

2012

Volltextzugriff (PDF)

Pharmacokinetics of Ibuprofen Enantiomers in Children with Cystic Fibrosis

Journal of clinical pharmacology, 2000-08, Vol.40 (8), p.861-868

2000

Volltextzugriff (PDF)

Long term results of lung transplantation for cystic fibrosis

European journal of cardio-thoracic surgery, 2002-10, Vol.22 (4), p.602-609

2002

Volltextzugriff (PDF)

The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis

The Journal of pediatrics, 1999, Vol.134 (1), p.58-63

1999

Volltextzugriff (PDF)

84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial

Journal of cystic fibrosis, 2011, Vol.10, p.S22-S22

2011

Volltextzugriff (PDF)

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)

Journal of antimicrobial chemotherapy, 2011-10, Vol.66 (10), p.2398-2404

2011

Volltextzugriff (PDF)

Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis

Journal of cystic fibrosis, 2010, Vol.9, p.S54-S54

2010

Volltextzugriff (PDF)

Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function

American journal of respiratory and critical care medicine, 2011-03, Vol.183 (5), p.627-634

2011

Volltextzugriff (PDF)

Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF)

Journal of cystic fibrosis, 2008-06, Vol.7, p.S36-S36

2008

Volltextzugriff (PDF)

Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data

Journal of cystic fibrosis, 2008-06, Vol.7, p.S25-S25

2008

Volltextzugriff (PDF)

Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis

Pediatric pulmonology, 2007-09, Vol.42 (9), p.751-756

2007

Volltextzugriff (PDF)

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection

Pediatric pulmonology, 2008-01, Vol.43 (1), p.47-58

2008

Volltextzugriff (PDF)

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis

Pediatric pulmonology, 2007-07, Vol.42 (7), p.610-623

2007

Volltextzugriff (PDF)

40 Aztreonam lysine for inhalation (AZLI) for CF patients with P. aeruginosa (PA) infection

Journal of cystic fibrosis, 2007, Vol.6, p.S10-S10

2007

Volltextzugriff (PDF)

Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard‐dose ibuprofen

Pediatric pulmonology, 2001-04, Vol.31 (4), p.314-316

2001

Volltextzugriff (PDF)

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis

Pediatric pulmonology, 2005-04, Vol.39 (4), p.339-348

2005

Volltextzugriff (PDF)

Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

Pediatric pulmonology, 2006-07, Vol.41 (7), p.656-665

2006

Volltextzugriff (PDF)

148 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: final results from a 192-week extension study

Journal of cystic fibrosis, 2024-09, Vol.23, p.S82-S83

2024

Volltextzugriff (PDF)

47: A new path for CF clinical trials through the use of historical controls

Journal of cystic fibrosis, 2021-11, Vol.20, p.S24

2021

Volltextzugriff (PDF)

133 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study

Journal of cystic fibrosis, 2023-10, Vol.22, p.S70-S71

2023

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Humans
(27)
Respiratory System
(23)
Female
(21)
Biological And Medical Sciences
(20)
Male
(20)
Medical Sciences
(19)
Child
(15)
Cystic Fibrosis
(15)
Adolescent
(14)
Cystic Fibrosis - Drug Therapy
(14)
Pediatrics
(14)
Administration, Inhalation
(13)
Treatment Outcome
(13)
Child, Preschool
(11)
Adult
(10)
Anti-Bacterial Agents - Administration & Dosage
(10)
Pulmonary/respiratory
(10)
Pharmacology. Drug Treatments
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis

Inflammatory and Microbiologic Markers in Induced Sputum after Intravenous Antibiotics in Cystic Fibrosis

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species ( BURK ) infection: final results from a randomized, placebo-controlled trial

58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection

Pharmacokinetics of Ibuprofen Enantiomers in Children with Cystic Fibrosis

Long term results of lung transplantation for cystic fibrosis

The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis

84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)

Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis

Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function

Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF)

Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data

Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis

40 Aztreonam lysine for inhalation (AZLI) for CF patients with P. aeruginosa (PA) infection

Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard‐dose ibuprofen

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis

Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

148 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: final results from a 192-week extension study

47: A new path for CF clinical trials through the use of historical controls

133 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study

Suchergebnisse filtern